ArticleThe Journal of clinical investigation1986
Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils.
Article in The Journal of clinical investigation, 1986. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
126 citing papers in PubMed, 575 citations in OpenAlex.
- Inhaled budesonide fails to inhibit the PAF-induced increase in plasma leukotriene B4 in man.British journal of clinical pharmacology · 1992Trial
- PAF. A review of its effects, antagonists and possible future clinical implications (Part II).Drugs · 1991Trial
- Trial
- Effect of a PAF antagonist, BN52063, on PAF-induced bronchoconstriction in normal subjects.British journal of clinical pharmacology · 1988Trial
- Eosinophil biology in COPD: from scientific insight to clinical treatment action.ERJ open research · 2026Review
- Hematopoietic and eosinophil-specific LNK(SH2B3) deficiency promotes eosinophilia and arterial thrombosis.Blood · 2024Article
- Effects of Lidocaine-Derived Organic Compounds on Eosinophil Activation and Survival.Molecules (Basel, Switzerland) · 2023Article
- Sensory Phenotype of the Oesophageal Mucosa in Gastro-Oesophageal Reflux Disease.International journal of molecular sciences · 2023Review
- [Allergic reactions to bioimplants].HNO · 2022Review
- UVB-Induced Microvesicle Particle Release and Its Effects on the Cutaneous Microenvironment.Frontiers in immunology · 2022Review
- The Enigma of Eosinophil Degranulation.International journal of molecular sciences · 2021Review
- Emerging Role of Phospholipase-Derived Cleavage Products in Regulating Eosinophil Activity: Focus on Lysophospholipids, Polyunsaturated Fatty Acids and Eicosanoids.International journal of molecular sciences · 2021Review
- New Insights Into the Pathologic Roles of the Platelet-Activating Factor System.Frontiers in endocrinology · 2021Review
- Repositioning Vitamin C as a Promising Option to Alleviate Complications associated with COVID-19.Infection & chemotherapy · 2020Review
- Mechanisms of eosinophilic inflammation.Asia Pacific allergy · 2020Review
- Platelet-Activating Factor-Induced Reduction in Contact Hypersensitivity Responses Is Mediated by Mast Cells via Cyclooxygenase-2-Dependent Mechanisms.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Serum from the Human Fracture Hematoma Contains a Potent Inducer of Neutrophil Chemotaxis.Inflammation · 2018Article
- An Inflammation-Centric View of Neurological Disease: Beyond the Neuron.Frontiers in cellular neuroscience · 2018Review
- Regulation of Eosinophil and Group 2 Innate Lymphoid Cell Trafficking in Asthma.Frontiers in medicine · 2017Article
- Lack of Platelet-Activating Factor Receptor Attenuates Experimental Food Allergy but Not Its Metabolic Alterations regarding Adipokine Levels.BioMed research international · 2016Article
66 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet-activating factor (PAF-acether), an inflammatory mediator with a wide range of biological activities including neutrophil aggregation and chemotaxis, was studied for its effect on human eosinophil locomotion (chemotaxis and chemokinesis). Human eosinophils (25-95% purity) were obtained from donors with a variety of diseases associated with hypereosinophilia. PAF-acether elicited directional locomotion of eosinophils, in a time- and dose-dependent fashion, at concentrations from 10(-5) to 10(-8) M; lyso-PAF had minimal activity over the same dose range. Compared with PAF-acether, the eosinophil locomotory responsiveness of leukotriene B4 (LTB4), histamine, and the valyl- and alanyl-eosinophil chemotactic factor of anaphylaxis (ECF-A) tetrapeptides was negligible. Conversely, neutrophil responsiveness to PAF-acether (optimum 10(-6) M) was comparable in effect to LTB4 (optimum dose 10(-8) M). It was shown that PAF-acether elicited both chemotaxis and chemokinesis of eosinophils. Comparison of normal density and light density eosinophils revealed no qualitative difference in the response to PAF-acether and the other chemoattractants, although the light density cells seemed to demonstrate a greater degree of locomotion to PAF-acether and LTB4. Thus, PAF-acether appears to be a potent eosinophilotactic agent which may play a role in inflammatory reactions characterized by eosinophil infiltration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.